SPECIALISATION:
Exclusively working in lentivirus
CDMO BUSINESS MODEL:
Covering the different phases
CUTTING-EDGE TECHNOLOGIES:
Seal of Excellence from European Commission
SCIENTIFIC EXPERTISE:
Own lentivirus-based technology (Lentisoma)
CUSTOMISED APPROACH TO PROJECTS:
From the technical and timeline point of view
BROAD EXPERTISE AND EXPERIENCE OF OUR TEAM:
More than 50 lentiviral batches manufactured at final scale
THE MOST INNOVATIVE EQUIPMENT AVAILABLE:
- iCELLis® bioreactor technology
- Compatible equipment at R&D and GMP suites
- More than 1600 m2 (17000 ft2) labs
MANUFACTURING PLATFORM DEVELOPMENT:
- Improved transient transfection method
- Increased final yield compared with regular protocols
POTENTIALITY:
Facilities, capability and infrastructure to increase current capacity
INTERNATIONAL COMPANY:
US and European customers
